Konruns(SH:603590) Zheng Quan Shi Bao Wang·2026-01-07 14:43Group 1 - The core viewpoint of the article is that Kangchen Pharmaceutical (603590) has announced a significant increase in its expected net profit for 2025, projecting a range of 145 million to 175 million yuan, which represents a year-on-year growth of 243.00% to 315.00% [2] Group 2 - On January 7, Kangchen Pharmaceutical's stock closed at 41.88 yuan, reflecting a 3.25% increase, with a turnover rate of 2.44% and a trading volume of 160 million yuan [2] - Over the past five days, the stock has risen by 3.51% [2] - A statistical analysis of stocks with a profit forecast increase of over 50% shows that 68.75% of these stocks experienced a price increase on the day of the announcement, with one stock hitting the daily limit [2] - Additionally, 75.00% of these stocks saw price increases within five days following the announcement [2] - In terms of capital flow, Kangchen Pharmaceutical experienced a net inflow of 5.402 million yuan today, with a total net inflow of 5.5694 million yuan over the past five days [2]